ZAZIBONA, the collaborative initiative of the Southern African Development Community Medical Products Regulatory Harmonisation (SADC MRH) is inviting applicants and pharmaceutical manufacturers to submit an Expression of Interest for Product Evaluation utilising the ZAZIBONA Centralised Pathway (ZAZIBONA CP). Applicants using the CP will receive a scientific opinion on the quality of their product. The scientific opinion serves as a recommendation to the participating Member States. All 16 SADC Member States participate either as Active or Non-Active Member States, based on their internal capacity to conduct
assessments and current Good Manufacturing Practice (cGMP) inspections, or as Observers2.
Positive recommendations can be used by applicants for expedited review and registration with the participating Active Member States at the time of lodging an application for registration (marketing authorisation). The Heads of Agencies have made a written commitment to finalise applications supported by a ZAZIBONA CP recommendation within 90 days of submission. This call for EOIs covers a period of 18months, that is, from July 2025 to December 2026.
Full Document: